Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

A phase 2 trial evaluated elotuzumab combined with pomalidomide, bortezomib, and dexamethasone (elo-PVd) in 48 patients with relapsed/refractory multiple myeloma. The overall response rate (ORR) was 56.3%, with a median progression-free survival (PFS) of 10 months. Patients with one prior therapy achieved a 73.7% ORR and 23.4-month PFS. Elo-PVd showed efficacy across diverse prior treatments, including anti-CD38 antibodies, with manageable safety outcomes.